Design, synthesis and in vitro drug release investigation of new potential 5-FU prodrugs. 2011

Pierre Daumar, and Caroline Decombat, and Jean-Michel Chezal, and Eric Debiton, and Michel Madesclaire, and Pascal Coudert, and Marie-Josèphe Galmier
Clermont Université, Université d'Auvergne, Imagerie moléculaire et thérapie vectorisée, BP 10448, F-63000 Clermont-Ferrand, France.

In order to identify new efficient prodrugs of 5-fluorouracil (5-FU) and to develop an original targeting approach using 2-fluoro-2-deoxyglucose (FDG) as a potential drug carrier, eight original 5-FU derivatives were synthesized: 5-FU was attached by the N1 position of the pyrimidinic ring to the C1 position of the FDG structure either by direct coupling (2a) or via various spacers (3, 6a-c, 10b and 19). A new sensitive high-performance liquid chromatography method was developed to simultaneously quantify 5-FU and its derivatives in human plasma and other relevant media at physiological temperatures. Half-lives were determined from the degradation profiles of these conjugates. Slow degradation of compounds 2a, 3, 10b and 19 was observed in vitro at 37 °C, but no 5-FU release was noticed. By contrast, the in vitro drug release profiles of compounds 6a-c followed pseudo-first-order kinetics, and 5-FU was found in all the media. The antiproliferative activity of the eight compounds was assessed in vitro by a fluorometric assay against two human solid cancer cell lines and one healthy cell line. A correlation was found between the activities of the compounds and their ability to release 5-FU efficiently.

UI MeSH Term Description Entries
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Pierre Daumar, and Caroline Decombat, and Jean-Michel Chezal, and Eric Debiton, and Michel Madesclaire, and Pascal Coudert, and Marie-Josèphe Galmier
January 1998, Journal of pharmaceutical sciences,
Pierre Daumar, and Caroline Decombat, and Jean-Michel Chezal, and Eric Debiton, and Michel Madesclaire, and Pascal Coudert, and Marie-Josèphe Galmier
August 2010, International journal of pharmaceutics,
Pierre Daumar, and Caroline Decombat, and Jean-Michel Chezal, and Eric Debiton, and Michel Madesclaire, and Pascal Coudert, and Marie-Josèphe Galmier
April 2001, International journal of pharmaceutics,
Pierre Daumar, and Caroline Decombat, and Jean-Michel Chezal, and Eric Debiton, and Michel Madesclaire, and Pascal Coudert, and Marie-Josèphe Galmier
May 2003, Journal of pharmaceutical sciences,
Pierre Daumar, and Caroline Decombat, and Jean-Michel Chezal, and Eric Debiton, and Michel Madesclaire, and Pascal Coudert, and Marie-Josèphe Galmier
January 2002, International journal of pharmaceutics,
Pierre Daumar, and Caroline Decombat, and Jean-Michel Chezal, and Eric Debiton, and Michel Madesclaire, and Pascal Coudert, and Marie-Josèphe Galmier
June 2011, The Journal of pharmacy and pharmacology,
Pierre Daumar, and Caroline Decombat, and Jean-Michel Chezal, and Eric Debiton, and Michel Madesclaire, and Pascal Coudert, and Marie-Josèphe Galmier
May 1996, Biomaterials,
Pierre Daumar, and Caroline Decombat, and Jean-Michel Chezal, and Eric Debiton, and Michel Madesclaire, and Pascal Coudert, and Marie-Josèphe Galmier
May 2018, ACS applied materials & interfaces,
Pierre Daumar, and Caroline Decombat, and Jean-Michel Chezal, and Eric Debiton, and Michel Madesclaire, and Pascal Coudert, and Marie-Josèphe Galmier
October 2005, Farmaco (Societa chimica italiana : 1989),
Pierre Daumar, and Caroline Decombat, and Jean-Michel Chezal, and Eric Debiton, and Michel Madesclaire, and Pascal Coudert, and Marie-Josèphe Galmier
September 1982, Journal of medicinal chemistry,
Copied contents to your clipboard!